Brain Health Assessment for Dementia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Kaiser Permanente Northgate Medical Center, Seattle, WA
Dementia+1 More
Brain Health Assessment - Other
Eligibility
65+
All Sexes
What conditions do you have?
Select

Study Summary

The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.

Eligible Conditions

  • Dementia
  • Alzheimer Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: 3 months after invitation mailed

Year 1
Clinic "no shows"
Hospitalizations
Medication adherence
Urgent care/emergency department visits
Month 12
New dementia diagnoses
New diagnoses of mild cognitive impairment
Positive predictive value of eRADAR algorithm
Month 3
Rate of accepting brain health visit
Month 6
Dementia medications
Healthcare utilization
Month 18
New dementia diagnoses (secondary definitions)

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Usual care
1 of 2
Brain Health Intervention
1 of 2
Active Control
Experimental Treatment

4050 Total Participants · 2 Treatment Groups

Primary Treatment: Brain Health Assessment · No Placebo Group · N/A

Brain Health Intervention
Other
Experimental Group · 1 Intervention: Brain Health Assessment · Intervention Types: Other
Usual careNoIntervention Group · 1 Intervention: Usual care · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months after invitation mailed
Closest Location: Kaiser Permanente Northgate Medical Center · Seattle, WA
Photo of Seattle 1Photo of Seattle 2Photo of Seattle 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Dementia
0 CompletedClinical Trials

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor
496 Previous Clinical Trials
22,182,137 Total Patients Enrolled
8 Trials studying Dementia
16,100 Patients Enrolled for Dementia
University of California, San FranciscoOTHER
2,246 Previous Clinical Trials
11,469,624 Total Patients Enrolled
28 Trials studying Dementia
12,611 Patients Enrolled for Dementia
Sascha Dublin, MD, PhDPrincipal InvestigatorKP Washington Health Research Institute
Deborah Barnes, PhDPrincipal InvestigatorUniversity of California, San Francisco

Eligibility Criteria

Age 65+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You do not have a prior diagnosis of dementia and you are not receiving medications for dementia.
You are a patient at a participating clinic.
The eRADAR score is a quantitative measurement of the radar cross section of a target.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.